Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
840 ARTICLES BY Jacob Bell
-
Pfizer makes sure it won't get left out of the gene therapy deal boom
March 20, 2019 -
Sage's postpartum depression drug is approved. Now comes the hard part
March 19, 2019 -
Dermira shares double on positive eczema data
March 18, 2019 -
Amgen not done in quest to prove Repatha
March 15, 2019 -
Sandoz CEO to depart as Novartis doubles down on biosimilars
March 14, 2019 -
Dupixent label expansion opens door to thousands more patients
March 12, 2019 -
Axovant buoyed by early gene therapy data
March 11, 2019 -
AMAG pregnancy drug's future in doubt after key study miss
March 8, 2019 -
Roche outbid competing biopharma to secure Spark deal
March 7, 2019 -
Gilead scores key HIV data as Descovy proves non-inferior to Truvada
March 6, 2019 -
5 takeaways from Scott Gottlieb's surprising FDA departure
March 6, 2019 -
Biogen avoids heavy manufacturing lift in latest gene therapy deal
March 5, 2019 -
Biogen buys Nightstar in search of more eye gene therapies
March 4, 2019 -
AbbVie, Akcea benefit from latest CHMP recommendations
March 1, 2019 -
So far, so good for Alexion's Soliris follow-on
Feb. 28, 2019 -
Bristol-Myers hits a bump on road to Celgene takeover
Feb. 28, 2019 -
AstraZeneca's PARP drug succeeds in pancreatic cancer study
Feb. 27, 2019 -
Pharmacquired: What would a Clovis takeout look like?
Feb. 26, 2019 -
Roche acquires Spark in $4.8B gene therapy play
Feb. 25, 2019 -
Intercept stock drop reflects the high bar set for NASH drugs
Feb. 22, 2019 -
Allogene inks lease for new cell therapy manufacturing facility
Feb. 21, 2019 -
Merck takes a shot on Immune Design
Feb. 21, 2019 -
Pfizer tweaks Xeljanz trial after embolism safety signal
Feb. 20, 2019 -
CMS unveils CAR-T proposal, with emphasis on patient outcomes
Feb. 15, 2019 -
AstraZeneca retires Medimmune name amid sales turnaround
Feb. 14, 2019